Rezolute, Inc.

NEWS

Clinical Catch-Up: Moderna COVID-19 Vaccine for Kids and Much More

Although it was relatively quiet in COVID-19-related clinical trials, there was plenty of other clinical trial news. Here’s a look.

March 25, 2022

10 min read

Mark Terry

Business

BioSpace Movers & Shakers, March 12

Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

March 11, 2021

7 min read

Alex Keown

JOBS

IN THE PRESS

Biotech Bay

Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)

March 6, 2024

8 min read

Business

Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update

February 13, 2024

8 min read

Deals

Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer

January 24, 2024

5 min read

Biotech Bay

Rezolute Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism

January 23, 2024

6 min read

Drug Development

Rezolute Initiates Phase 3 Clinical Study for RZ358 in Congenital Hyperinsulinism

December 14, 2023

8 min read

Drug Development

Rezolute Completes Enrollment of its Phase 2 Study in Diabetic Macular Edema (“DME”)Plans to report topline data mid-second quarter 2024

December 13, 2023

6 min read

Lone Star Bio

Stonegate Healthcare Partners Announces Black Friday Biotech Special Report For an “XBI-MAS”

November 27, 2023

1 min read

Biotech Bay

Rezolute to Participate in BTIG’s 3rd Annual Ophthalmology Day

November 17, 2023

3 min read

Business

Rezolute Reports First Quarter Fiscal 2024 Results

November 13, 2023

6 min read

Policy

Rezolute Receives Priority Medicines (PRIME) Eligibility from European Medicines Agency for Enhanced Regulatory Support of RZ358 in Congenital Hyperinsulinism

October 17, 2023

6 min read